Global Myasthenia Gravis Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. Scope of the Report: This report focuses on the Myasthenia Gravis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies. The worldwide market for Myasthenia Gravis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers Flamel Technologies Roche Grifols Pfizer Shire Novartis Valeant Alexion Catalyst CSL Curavac Cytokinetics Galencia GlaxoSmithKline Lupin Pharmaceuticals Mitsubis ...
Table of Contents 1 Market Overview 1.1 Myasthenia Gravis Drugs Introduction 1.2 Market Analysis by Type 1.2.1 Anticholinesterases 1.2.2 Immunosuppressants 1.2.3 Intravenous Immune Globulins 1.3 Market Analysis by Applications 1.3.1 Hospitals 1.3.2 Clinics 1.4 Market Analysis by Regions 1.4.1 North America (United States, Canada and Mexico) 1.4.1.1 United States Market States and Outlook (2013-2023) 1.4.1.2 Canada Market States and Outlook (2013-2023) 1.4.1.3 Mexico Market States and Outlook (2013-2023) 1.4.2 Europe (Germany, France, UK, Russia and Italy) 1.4.2.1 Germany Market States and Outlook (2013-2023) 1.4.2.2 France Market States and Outlook (2013-2023) 1.4.2.3 UK Market States and Outlook (2013-2023) 1.4.2.4 Russia Market States and Outlook (2013-2023) 1.4.2.5 Italy Market States and Outlook (2013-2023) ...
4077

1153

OUR CLIENT